Krebsforum Lazarus

Bitte loggen sie sich ein oder registrieren sie sich.

Einloggen mit Benutzername, Passwort und Sitzungslänge
Erweiterte Suche  

Autor Thema: National Cancer Institute (NCI), Cancner Bulletin  (Gelesen 1298 mal)

Khan

  • Globaler Moderator
  • Vollwertiges Mitglied
  • *****
  • Beiträge: 193
National Cancer Institute (NCI), Cancner Bulletin
« am: 11. Februar 2011, 05:15:39 »

http://www.cancer.gov/ncicancerbulletin/

http://www.cancer.gov/

"Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases."



Right now:

"When Combined with Chemo, Bevacizumab Is Associated with Increased Risk of Death

Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was conducted by researchers at Stony Brook University School of Medicine in New York. The risk of fatal adverse events varied by the type of chemotherapy agents used with bevacizumab, lead author Dr. Vishal Ranpura and his colleagues reported."

Read more:
http://www.cancer.gov/ncicancerbulletin/020811/page2
Gespeichert